Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Dyne Therapeutics, Inc. has received an average rating of "Buy" from 17 research firms, with a consensus price objective of $34.94.
• CEO John Cox purchased 100,000 shares of the company's stock for $911,000, increasing his ownership by 70.33%.
• Institutional investors own 96.68% of Dyne Therapeutics, indicating strong confidence from large investment firms in the company's future.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average rating of "Buy" by the seventeen research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $34.9375.

A number of research firms recently issued reports on DYN. Chardan Capital decreased their price objective on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, July 29th. JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Evercore ISI reiterated an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Royal Bank Of Canada decreased their price objective on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, July 29th. Finally, Jones Trading began coverage on Dyne Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $30.00 price objective for the company.

Insider Activity

In related news, CEO John Cox bought 100,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were purchased at an average cost of $9.11 per share, with a total value of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares of the company's stock, valued at $2,206,250.69. This represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Dyne Therapeutics in the 4th quarter valued at about $50,000. GAMMA Investing LLC increased its position in Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after buying an additional 2,345 shares in the last quarter. CWM LLC increased its position in Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after buying an additional 1,900 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Finally, Quarry LP bought a new stake in Dyne Therapeutics in the 1st quarter valued at about $47,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Trading Up 0.7%

NASDAQ:DYN opened at $11.24 on Tuesday. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45. The business's 50-day moving average price is $10.59 and its two-hundred day moving average price is $11.30. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -2.91 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, equities analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.